GEN Exclusives

More »

GEN News Highlights

Back to Item »

FDA Issues Novartis with CRL Requesting Additional Safety Data on Gouty Arthritis Drug

Agency says it can’t approve canakinumab without further evaluation of benefit/risk profile in refractory patients.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Career Development Woes

What do you consider the greatest threat to your career prospects?

More »